ISPOR Leaders Named PharmaVOICE 100 Honorees

Published Aug 2, 2017
Immediate Past-President Professor Lou Garrison and CEO Nancy Berg Recognized as Inspirational Leaders in the Life Sciences Princeton, NJ—August 2, 2017—Two leaders of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) have been named to the renowned list of 2017 PharmaVOICE 100 honorees. Immediate Past-President Lou Garrison, PhD and Chief Executive Officer and Executive Director Nancy S. Berg have been named 2017 PharmaVOICE 100 honorees by PharmaVOICE magazine. Dr. Garrison is Professor Emeritus in the Pharmaceutical Outcomes Research and Policy Program in the School of Pharmacy at the University of Washington. He is a long-term volunteer leader for ISPOR and currently serves in the role of Immediate Past-President. Dr. Garrison is identified as a Change Agent and is described by PharmaVOICE as a global thought leader and teacher in health economics and outcomes research (HEOR) who travels the globe to advance the field. Ms. Berg was recruited in 2014 to head ISPOR, the leading global scientific and educational organization for HEOR. Identified as a Commander and Chief and described as a strategic transformer by PharmaVOICE, Ms. Berg has worked closely with the Society’s Board of Directors to further ISPOR’s mission to advance HEOR excellence to improve decision making for health globally. The PharmaVOICE 100 was established thirteen years ago by PharmaVOICE magazine and is an annual list of inspirational individuals recognized for their positive contributions to the life-sciences industry. The PharmaVOICE 100 honorees represent a broad cross-section of the global life-sciences industry, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, advertising, digital, marketing, technology, academia, and many other sectors. This diverse group of individuals also represents a wide variety of functional areas ranging from the clinic to the C-suite.

###

  ABOUT ISPOR The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that promotes health economics and outcomes research excellence to improve decision making for health globally. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: http://bit.ly/ISPOR-T (@ISPORorg) | YouTube: http://bit.ly/ISPOR-YT | Facebook: http://bit.ly/ISPOR-FB  

Related Stories

ISPOR Announces 2025-2026 Board of Directors

May 20, 2025

ISPOR announced the results of its recent elections and its 2025-2026 Board of Directors. The 2025-2026 board will assume office on July 1.

Value in Health Journal Spotlights "Whole Health" in Special Series

May 19, 2025

Value in Health, the official journal of ISPOR, announced the publication of a series of articles exploring the concept of "whole health"—a holistic approach to healthcare that extends beyond the traditional biomedical model to incorporate physical, mental, social, environmental, and spiritual dimensions of wellbeing.

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×